Patents by Inventor Anthony CAO

Anthony CAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20230027495
    Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
    Type: Application
    Filed: November 6, 2020
    Publication date: January 26, 2023
    Applicants: Genmab A/S, MSD International GmbH
    Inventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
  • ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT
    Publication number: 20220298243
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Application
    Filed: April 7, 2022
    Publication date: September 22, 2022
    Applicants: Bristol-Myers Squibb Company, Seattle Genetics, Inc.
    Inventors: Benedetto FARSACI, Neil JOSEPHSON, Anthony CAO, Ryan HEISER
  • Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment
    Patent number: 11299543
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: April 12, 2022
    Assignees: Bristol-Myers Squibb Company, Seattle Genetics. Tnc.
    Inventors: Benedetto Farsaci, Neil Josephson, Anthony Cao, Ryan Heiser
  • METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20220088191
    Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
    Type: Application
    Filed: May 7, 2019
    Publication date: March 24, 2022
    Applicants: MSD International GmbH
    Inventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
  • METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20210107980
    Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
    Type: Application
    Filed: May 7, 2019
    Publication date: April 15, 2021
    Inventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
  • USE OF AN ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT
    Publication number: 20190218293
    Abstract: The application provides to methods for treating Hodgkin lymphoma or non Hodgkin lymphoma in a subject comprising—nivolumab, or pembrolizumab, two PD-1-blocking antibodies that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma in combination with—an anti CD30 antibody, such as brentuximab vedotin.
    Type: Application
    Filed: June 1, 2017
    Publication date: July 18, 2019
    Applicants: Bristol-Myers Squibb Company, Seattle Genetics, Inc.
    Inventors: Benedetto FARSACI, Neil JOSEPHSON, Anthony CAO, Ryan HEISER